Document Detail

Predictors of side effects during the buildup phase of venom immunotherapy for Hymenoptera venom allergy: the importance of baseline serum tryptase.
MedLine Citation:
PMID:  20542320     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Severe side effects during venom immunotherapy (VIT) are associated with a variety of risk factors. OBJECTIVE: Our aim was to evaluate the association of baseline serum tryptase concentration (BTC) and of other parameters, which are routinely recorded during patient evaluation, with the frequency of severe reactions requiring an emergency intervention during the buildup phase of VIT. METHODS: In this observational prospective multicenter study, we enrolled 680 patients with established honeybee or vespid venom allergy who underwent VIT. Data were collected on tryptase concentration, age, sex, culprit insect, cardiovascular medication, degree of preceding sting reaction, preventive antiallergic medication before therapy, time between last preceding sting reaction and VIT, venom specific IgE concentration, and type of buildup procedure. Relative rates were calculated with generalized additive models. RESULTS: Fifty-seven patients (8.4%) required an emergency intervention during buildup because of a severe systemic reaction. The frequency of interventions increased significantly with higher BTC (log-linear association; adjusted odds ratio, 1.56; 95% CI, 1.15-2.11; P < .005). The predictive power of BTC was markedly greater when VIT was performed for vespid venom allergy than for bee venom (for bee VIT, no significant association; for vespid VIT, log-linear association; adjusted odds ratio, 2.33; 95% CI, 1.28-4.26; P = .005). The most important other factor significantly associated with severe reactions during the buildup phase of VIT was bee venom allergy. CONCLUSION: Before vespid VIT, measurement of baseline serum tryptase concentration should be used to identify patients with a high risk for side effects. Patients with bee venom allergy require a particularly high degree of surveillance during VIT.
Franziska Ruëff; Bernhard Przybilla; Maria Beatrice Biló; Ulrich Müller; Fabian Scheipl; Werner Aberer; Joëlle Birnbaum; Anna Bodzenta-Lukaszyk; Floriano Bonifazi; Christoph Bucher; Paolo Campi; Ulf Darsow; Cornelia Egger; Gabrielle Haeberli; Thomas Hawranek; Iwona Kucharewicz; Helmut Küchenhoff; Roland Lang; Oliviero Quercia; Norbert Reider; Maurizio Severino; Michael Sticherling; Gunter Johannes Sturm; Brunello Wüthrich;
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-06-12
Journal Detail:
Title:  The Journal of allergy and clinical immunology     Volume:  126     ISSN:  1097-6825     ISO Abbreviation:  J. Allergy Clin. Immunol.     Publication Date:  2010 Jul 
Date Detail:
Created Date:  2010-07-12     Completed Date:  2010-07-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1275002     Medline TA:  J Allergy Clin Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  105-11.e5     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
Department of Dermatology and Allergology, Ludwig-Maximilians-Universität, Munich, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arthropod Venoms / immunology*
Desensitization, Immunologic / adverse effects*
Hymenoptera / immunology*
Hypersensitivity / blood,  therapy*
Middle Aged
Risk Factors
Tryptases / blood*
Reg. No./Substance:
0/Arthropod Venoms; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hospice enrollment for terminally ill patients with gynecologic malignancies: impact on outcomes and...
Next Document:  Low-dose, but not high-dose, cyclosporin A promotes regulatory T-cell induction, expansion, or both.